FEN PHEN INFORMATION

About Wyeth-Ayerst Laboratories

Wyeth has a long history of pioneering developments in pharmaceuticals and biotechnology, with leading products in the areas of women’s health care, neuroscience, musculoskeletal disorders, cardiovascular therapy, vaccines and infectious disease, hemophilia, immunology, and oncology. Wyeth is also a leader in the development of nutritional.


Wyeth is a leader in women’s health care with postmenopausal hormone therapy products for women, as well as hormone-based oral contraceptive products. Research in women’s health continues to be a priority at Wyeth, with extensive R&D under way in the area of postmenopausal hormone therapy.


Dexfenfluramine is manufactured for Interneuron Pharmaceuticals and marketed under the name of Redux by Wyeth-Ayerst Laboratories, a subsidiary of American Home Products Corp. of Madison, N.J., which also manufactures and markets fenfluramine under the brand name Pondimin. Both companies have agreed to voluntarily withdraw their drugs. The FDA is not requesting the withdrawal of phentermine, the third widely used medication for obesity.


Pondimin and Redux, each of which is a form of fenfluramine (the “fen” component in the diet drug known as fen-phen). When Pondimin or Redux were given with phentermine (the “phen” ingredient of fen-phen), the combination was known as “fen-phen


FEN PHEN SIDE EFFECTS

Findings suggest fenfluramine and dexfenfluramine are the likely cause of heart valve problems of the type that prompted FDA’s two earlier warnings concerning “fen-phen,” a combination of fenfluramine and phentermine. “Fen-phen” has been widely used off-label in recent years for the long-term management of obesity

In July 1997, researchers at the Mayo Clinic and Mayo Foundation reported 24 cases of rare valvular disease in women who took the “fen-phen” combination therapy. FDA alerted medical doctors that it had received nine additional reports of the same type, and requested all health care professionals to report any such cases to the agency’s MedWatch program



FEN PHEN CLASS ACTION LAWSUIT

A class action lawsuit was filed


FEN PHEN RECALL

The Food and Drug Administration, acting on new evidence about significant side-effects associated with fenfluramine and dexfenfluramine, has asked the manufacturers to voluntarily withdraw both treatments for obesity from the market. When the FDA notified American Home Products (the maker of the drug duo) of the problem, the drugs were pulled from the marketplace. The damage had already been done. As many as six million people are believed to have obtained prescriptions for the drug combination.

FINDING A FEN PHEN CLASS ACTION LAWSUIT LAWYER

The law firms featured at the top of the page can assist you with filing your claim in the Fen Phen Class Action Lawsuit, or in filing a seperate lawsuit, outside the Class Action. American Home Products proposed to pay out upwards of four billion dollars to settle fen-phen related cases. A state district judge has granted class-action status for a lawsuit seeking free medical screenings for any Texans who used the diet drug combination fen-phen.